An attempt at conservative treatment in selected cases of type I endometrial carcinoma (Stage I A/G1) in young women

European Journal of Gynaecological Oncology

Volumn 30, Issue 4, 2009, Pages 365-369

  Stanosz, S ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Bromocriptine; Endometrial carcinoma; Metformin; Mucous membrane; Sex hormones; Uterus

Indexed keywords

ERGOCRYPTINE; ESTRADIOL; ESTRIOL; ESTRONE; METFORMIN; METOCLOPRAMIDE; PROGESTERONE; PROLACTIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CURETTAGE; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MENSTRUAL CYCLE; ULTRASOUND;

ADULT; BROMOCRIPTINE; DILATATION AND CURETTAGE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTRIOL; FEMALE; HUMANS; METFORMIN; PROGESTERONE; YOUNG ADULT;

EID: 68849089020     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Pisani P., Parkin D.M., Muñoz N.F. Related Articles, Ferlay J.: "Cancer and infection: estimates of the attributable fraction in 1990". Cancer Epidemiol. Biomarkers, 1997, 6, 387. (Pubitemid 27270542)
2. Bergström A., Pisani P., Tenet V., Wolk A., Adami H.O.: "Overweight as an avoidable cause of cancer in Europe". Int. J. Cancer, 2001, 92, 421.
3. Hill H.A., Austin H.A.: "Nutrition and endometrial cancer". Cancer Causes Control., 1996, 7, 11.
4. Emons G., Fleckenstein G., Hinney B., Huschmand A., Heyl W.: "Hormonal interactions in endometrial cancer". Endocr. Relat. Cancer, 2000, 7, 227.
5. Sherman M.E.: "Theories of endometrial carcinogenesis: a multidisciplinary approach". Mod. Pathol., 2000, 13, 295.
6. Bonfitto V.L., de Andrade L.A.: "P53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy". São Paulo Med. J., 2003, 121, 163.
7. Dahmoun M., Bäckström T., Boman K., Cajander S.: "Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis". Int. J. Oncol., 2003, 22, 115.
8. Mutter G.L., Baak J.P., Fitzgerald J.T., Gray R., Neuberg D., Kust G.A., Gentleman R., Gullans S.R., Wei L.J., Wilcox M.: "Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation". Gynecol. Oncol., 2001, 83, 2, 77. (Pubitemid 33033052)
9. Cerezo L., Cárdenes H., Michael H.: "Molecular alterations in the pathogenesis of endometrial adenocarcinoma". Clin. Trans. Oncol., 2006, 8, 231.
10. Iida K., Imai A., Tamaya T.: "Estriol binding in uterine corpus cancer and normal uterine tissues". Gen. Pharmacol., 1991, 22, 491.
11. Randall T.C., Kurman R.J.: "Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40". Obstet. Gynecol., 1997, 90, 434.
12. Kauppila A.: "Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations". Acta Obstet. Gynecol. Scand., 1984, 63, 441.
13. Araujo Junior N.L., Athanazio D.A.: "Hormone replacement therapy and endometrial cancer". Cad Saude Publica, 2007, 23, 2613.
14. Doren M.: "Hormonal replacement regimens and bleeding". Maturitas, 2000, 14, 17.
15. Kauppila A., Isotalo H., Kirkinen P., Mäkilä U.M., Orava M., Vihko R.: "Metoclopramide-induced hyperprolactinaemia: effects on corpus luteum function, endometrial steroid receptor concentrations and 17 beta-hydroxysteroid dehydrogenase activity". Clin. Endocrinol., 1987, 26, 145. (Pubitemid 17015700)